WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Whitehawk Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.01+0.12 (+4.15%)
Close on Oct 19, 2026
- Market cap
- $249.49M
- P/E (TTM)
- –
- Dividend yield
- –
Whitehawk Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $7.15M | $25.98M | $24.35M | $15.22M | $0 | – | – | – | 100.0% | -72.5% |
| License revenue | – | – | – | $0 | $1.00M | $14.00M | $20.00M | $20.00M | – | – |
| Grant revenue | – | – | – | $0 | $120.00K | $580.00K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Whitehawk Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.